

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**PASSING OF CONSISTENCY EVALUATION
FOR THE GROUP'S "CEFIXIME CAPSULES"**

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Cefixime Capsules (0.1g)" (the "**Product**") developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted approval by the National Medical Products Administration of the People's Republic of China for passing the consistency of quality and efficacy evaluation of generic drugs (the "**Consistency Evaluation**").

Cefixime is a cephalosporin antibiotic drug mainly used for the treatment of acute bronchitis caused by sensitive bacteria, pneumonia, secondary infection of chronic respiratory diseases, cystitis, pyelonephritis, gonococcal urethritis, cholecystitis, cholangitis, otitis media, paranasal sinusitis and scarlet fever.

Cefixime Capsules is one of the key anti-infection drug products of the Group, being the second of its kind for passing the Consistency Evaluation in China. Passing of the Consistency Evaluation indicates the consistency of the Product with the originator drug in terms of quality and efficacy, providing a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 27 November 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

** for identification purpose only*